IGF2BP2 has been implicated in suppressing anti-tumor immune responses, enhancing the function of immunosuppressive cells, adapting to hypoxic conditions, and driving cancer metabolism, angiogenesis, drug resistance, metastasis, and cell cycle progression. The gene discussed is IGF2BP2; the disease is cancer.